XRTX — XORTX Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$5.54m
- CA$4.16m
Brief: Xortx Announces Positive Topline Results From Pharmacokinetics Bridging Clinical Trial
Brief: Xortx Announces Pre-Phase 3 Meeting Request With Us Food And Drug Administration (FDA)
Brief: XORTX Opens An Ind For Xrx-008 Program For Autosomal Dominant Polycystic Kidney Disease
Brief: Xortx Initiates Dosing Of Human Subjects In The Xrx-Oxy-101 Clinical Trial
Brief: XORTX Receives Small And Medium Enterprise Status For The European Union
Brief: Xortx Announces Grant Of U.S. Patent
Brief: XORTX Files IND With FDA
Brief: Xortx Files New Percent Patent To Treat And Protect Individuals Most At Risk To Severe Viral Infection
Brief: XORTX Therapeutics Announces Submission Of Clinical Trial Application To Conduct Bridging Pharmacokinetics Study
Brief: XORTX Announces Appointment Of Chief Technology Officer
Brief: XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:00 PM
NASDAQ RESUMED AT 09:49 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Brief: Xortx Announces Results From Mount Sinai’s Covid-19 Clinical Study
Brief: Xortx Announces Grant Of European Patent
Brief: Xortx Therapeutics Inc - Applied Or Intend To Apply To List Common Shares On Either Nasdaq Or NYSE American And On TSX Venture Exchange
Brief: XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy
Brief: Xortx Announces Appointment Of CFO